1-3 of 3
Maria Undurraga Sutton
Close
Sort by
Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge E. Cortes, Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F. Apperley
Journal: Blood
Blood (2022) 140 (Supplement 1): 1495–1497.
https://doi.org/10.1182/blood-2022-157822
Published: 2022
Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Jane F. Apperley, Jorge E. Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael W. Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti
Journal: Blood
Blood (2022) 140 (Supplement 1): 6760–6762.
https://doi.org/10.1182/blood-2022-157956
Published: 2022
Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Clinical Trials & Observations
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Journal: Blood
Blood (2021) 138 (21): 2042–2050.
https://doi.org/10.1182/blood.2021012082
Published: 2021
Includes: Supplemental data